New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 8, 2011, Pages 3774-3781

  Johnson, Michael E ^a   Katiyar, Santosh K ^a   Edlind, Thomas D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; ANIDULAFUNGIN; CASPOFUNGIN; MEMBRANE PROTEIN; MICAFUNGIN; PROTEIN FKS1; PROTEIN FKS2; UNCLASSIFIED DRUG;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

ANTIFUNGAL AGENTS; BASE SEQUENCE; BETA-GLUCANS; CANDIDA GLABRATA; CELL WALL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; GLUCOSYLTRANSFERASES; LIPOPEPTIDES; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SCEDOSPORIUM; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA;

EID: 79960329629     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01811-10     Document Type: Article

References (36)

1. Baltz, R. H. 2009. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol. 13:144-151.
2. Castanheira, M., et al. 2010. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob. Agents Chemother. 54:2655-2659.
3. Cornely, O. 2008. Aspergillus to zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 36:296-313.
4. Cortez, K. J., et al. 2008. Infections caused by Scedosporium spp. Clin. Microbiol. Rev. 21:157-197.
5. Cuenca-Estrella, M., et al. 2009. Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob. Agents Chemother. 53:2192-2195.
6. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. (Pubitemid 37222342)
7. Douglas, C. M. 2001. Fungal β-(1,3)-D-glucan synthesis. Med. Mycol. 39(Suppl. 1):55-66.
8. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
9. Ferrari, S., et al. 2009. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5:1-17.
10. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
11. Garcia-Effron, G., S. Lee, S. Park, J. D. Cleary, and D. S. Perlin. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
12. Groll, A. H., and T. J. Walsh. 2001. Uncommon opportunistic fungi: new nosocomial threats. Clin. Microbiol. Infect. 7:8-24.
13. Jain, P., I. Akula, and T. Edlind. 2003. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 47:3195-3201.
14. Katiyar, S. K., and T. D. Edlind. 2009. Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 53:1772-1778.
15. Kauffman, C. A. 2006. Fungal infections. Proc. Am. Thorac. Soc. 3:35-40.
16. Kauffman, C. A., and P. L. Carver. 2008. Update on echinocandin antifungals. Semin. Respir. Crit. Care Med. 29:211-219.
17. Kontoyiannis, D. P., and R. E. Lewis. 2002. Antifungal drug resistance of pathogenic fungi. Lancet 359:1135-1144.
18. Krogh, A., B. Larsson, G. von Heijne, and E. L. L. Sonnhammer. 2001. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J. Mol. Biol. 305:567-580.
19. Kurtz, M. B., and J. H. Rex. 2001. Glucan synthase inhibitors as antifungal agents. Adv. Protein Chem. 56:423-475.
20. Malani, A. N., and C. A. Kauffman. 2007. Changing epidemiology of rare mould infections: implications for therapy. Drugs 67:1803-1812.
21. Martins, I. M., et al. 2011. Differential activities of three families of specific β(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeast. J. Biol. Chem. 286:3484-3496.
22. Mazur, P., et al. 1995. Differential expression and function of two homologous subunits of yeast 1,3-β-D-glucan synthase. Mol. Cell. Biol. 15:5671-5681.
23. Nakai, T., et al. 2003. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. 47:1376-1381.
24. Nucci, M., and E. Anaissie. 2007. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 20:695-704.
25. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
26. Parent, S. A., et al. 1993. Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae. J. Gen. Microbiol. 139:2973-2984.
27. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Res. Updat. 10:121-130.
28. Pfaller, M. A., and D. J. Diekema. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
29. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
30. Radding, J. A., S. A. Heidler, and W. W. Turner. 1998. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans. Antimicrob. Agents Chemother. 42:1187-1194.
31. Richardson, M., and C. Lass-Flörl. 2008. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect. 14:5-24.
32. Roemer, T., et al. 2003. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol. Microbiol. 50: 167-181.
33. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
34. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
35. Vermitsky, J.-P., and T. D. Edlind. 2004. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-Like transcription factor. Antimicrob. Agents Chemother. 48:3773-3781.
36. Xiao, L., et al. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574. (Pubitemid 38141718)